2020
Survival After Coronary Revascularization With Paclitaxel-Coated Balloons
Scheller B, Vukadinovic D, Jeger R, Rissanen TT, Scholz SS, Byrne R, Kleber FX, Latib A, Clever YP, Ewen S, Böhm M, Yang Y, Lansky A, Mahfoud F. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal Of The American College Of Cardiology 2020, 75: 1017-1028. PMID: 32138961, DOI: 10.1016/j.jacc.2019.11.065.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicHumansPaclitaxelRandomized Controlled Trials as TopicConceptsDrug-coated balloonsPaclitaxel-coated balloonRisk of deathCause mortalityRisk ratioStent restenosisPaclitaxel drug-coated balloonPaclitaxel-coated devicesDe novo lesionsCoronary artery diseaseSuperficial femoral arteryCochrane Library databasesConfidence intervalsNumber of patientsWeb of ScienceCardiac mortalityCoronary revascularizationNovo lesionsCoronary interventionDCB groupDifferent time pointsArtery diseasePrimary outcomeFemoral arteryPeripheral arteries
2012
Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. The American Journal Of Cardiology 2012, 110: 21-29. PMID: 22464212, DOI: 10.1016/j.amjcard.2012.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary AngiographyCoronary Artery DiseaseEverolimusFollow-Up StudiesHumansImmunosuppressive AgentsPaclitaxelProspective StudiesProsthesis DesignReproducibility of ResultsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsID-TLRAngiographic groupClinical followMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesDrug-eluting stent placementMajor adverse cardiovascular eventsBare metal stent implantationSPIRIT IIILandmark survival analysisSPIRIT III trialAdverse cardiovascular eventsSafety end pointCardiovascular event ratesIschemia-driven revascularizationMajor clinical outcomesPercutaneous coronary interventionDrug-eluting stentsRoutine AngiographicCardiovascular eventsCoronary revascularizationRevascularization ratesCoronary interventionIII trials
2010
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW, Investigators S. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1220-1228. PMID: 21232715, DOI: 10.1016/j.jcin.2010.07.017.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicAspirinClopidogrelConfidence IntervalsCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsProportional Hazards ModelsRandomized Controlled Trials as TopicRiskRisk Reduction BehaviorSirolimusTiclopidineTime FactorsConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsAdverse cardiac eventsTarget vessel failureCardiac eventsMyocardial infarctionSPIRIT IIProbable stent thrombosisAcademic Research ConsortiumEverolimus-eluting stentsVessel failureSignificant reductionLesion revascularizationPES patientsRevascularization eventsIII trialsClinical outcomesEE patientsStent thrombosisPooled analysisCumulative ratePersistent reductionSPIRIT IIIPatientsStentsComparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1229-1239. PMID: 21232716, DOI: 10.1016/j.jcin.2010.09.014.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary Artery BypassCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleHumansImmunosuppressive AgentsKaplan-Meier EstimateMaleMiddle AgedPaclitaxelRandomized Controlled Trials as TopicSirolimusTime FactorsUnited StatesConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionSPIRIT IV trialTarget lesion revascularizationVessel myocardial infarctionLesion revascularizationMultivessel diseaseMultivessel interventionAbsolute benefitMyocardial infarctionOptimal revascularization strategySingle-vessel interventionDe novo lesionsReference vessel diameterEverolimus-ElutingMultilesion interventionEfficacy outcomesNovo lesionsRevascularization strategyCoronary diseaseClinical outcomesCoronary arteryClinical safetySingle lesionComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6: 437-46. PMID: 20884430, DOI: 10.4244/eij30v6i4a75.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedPaclitaxelSirolimusConceptsPaclitaxel-eluting stentsClinical outcomesStent typeMajor adverse cardiac eventsTwo-year event ratesSPIRIT IIIPaclitaxel-eluting coronary stentsSPIRIT III trialYear clinical outcomesAdverse cardiac eventsCardiac eventsIII trialsPE groupTwo-vesselPatientsEvent ratesCoronary stentsTrialsVessel treatmentStentsOutcomesVesselsSignificant interactionStentingLesionsIntravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents
Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Leon MB, Moses JW, Stone GW. Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. The American Journal Of Cardiology 2010, 106: 952-957. PMID: 20854956, DOI: 10.1016/j.amjcard.2010.05.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicDrug-Eluting StentsEquipment FailureFemaleHumansMalePaclitaxelSirolimusTreatment OutcomeUltrasonography, InterventionalConceptsPaclitaxel-eluting stentsIntravascular ultrasound findingsSirolimus-eluting stentsUltrasound findingsStent fractureExternal elastic membrane areaClinical trial cohortSimilar frequencyComplete stent fracturePE fractureTrial cohortInstitutional cohortIVUS findingsStent lengthDistal fragmentIVUS featuresIVUS analysisCalcified plaquesStent fragmentsPatientsStrut fractureStentsMalalignmentCohortFractures
2009
Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction
Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA, Parise H, Mehran R, Stone GW. Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction. Circulation 2009, 120: 1875-1882. PMID: 19858413, DOI: 10.1161/circulationaha.109.873893.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsElevation myocardial infarctionPositive vessel remodelingMyocardial infarctionVolume obstructionStent malappositionMetal stentsAcute Myocardial Infarction trialVessel remodelingVolumetric intravascular ultrasound analysisIntravascular ultrasound substudyMyocardial Infarction trialPrespecified end pointAcute myocardial infarctionBlinded core laboratoryNew aneurysm formationIntravascular ultrasound analysisMedian stent lengthDrug-eluting stentsPaclitaxel-ElutingThrombus protrusionUltrasound substudySymptom onsetSPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease
Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. American Heart Journal 2009, 158: 520-526.e2. PMID: 19781409, DOI: 10.1016/j.ahj.2009.07.025.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion revascularizationCoronary artery diseaseSPIRIT IVLesion revascularizationArtery diseaseDiabetes mellitusIschemia-driven target lesion revascularizationNovo native coronary artery lesionsMajor adverse cardiac eventsNative coronary artery diseaseNative coronary artery lesionsTarget vessel myocardial infarctionEnd pointUS clinical sitesAdverse cardiac eventsPrimary end pointTarget lesion failureTarget vessel failureVessel myocardial infarctionCoronary artery lesionsReference vessel diameterClinical end pointsMulticenter clinical trialAngiographic late lossThe GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial. JACC Cardiovascular Interventions 2009, 2: 205-214. PMID: 19463427, DOI: 10.1016/j.jcin.2008.12.011.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsMajor adverse cardiac event ratesAdverse cardiac event ratesSingle de novo lesionsMajor adverse clinical eventsStent late lumen lossEnd pointBinary angiographic restenosisCardiac event ratePrimary end pointSecondary end pointsDe novo lesionsRandomized multicenter trialAdverse clinical eventsStent late lossLate lumen lossNative coronary arteriesStent restenosis rateBare metal stentsAngiographic restenosisNovo lesionsCoronary angiographyMulticenter trialRestenosis rateLumen loss
2008
A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB, Schofer J, Buchbinder M, Wijns W, Group C. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. Journal Of The American College Of Cardiology 2008, 51: 1543-1552. PMID: 18420096, DOI: 10.1016/j.jacc.2008.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicChromium AlloysClopidogrelCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDiabetes MellitusFemaleHumansMaleMiddle AgedPaclitaxelPlatelet Aggregation InhibitorsPolymersRiskThromboembolismTiclopidineTime FactorsConceptsPercutaneous coronary interventionTarget vessel revascularizationDrug-eluting stentsMajor adverse cardiac eventsMultivessel percutaneous coronary interventionTaxus drug-eluting stentsMyocardial infarctionAdjudicated deathAdverse cardiac eventsPrimary end pointSegment late lossSingle target lesionPre-specified subgroupsStent thrombosis ratesTreatment of SingleVessel revascularizationCardiac eventsCoronary interventionII studyThrombosis rateAngiographic analysisEpicardial vesselsTarget lesionsLate lossPatients
2007
Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis.
Sano K, Mintz GS, Carlier SG, Solinas E, Costa Jde R, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, Stone GW, Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. Journal Of Invasive Cardiology 2007, 19: 464-8. PMID: 17986721.Peer-Reviewed Original ResearchCobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).
Kaul U, Gupta RK, Mathur A, Dani S, Sapra R, Nayak PR, Lansky A, Cristea E, Carlier S, Gambone L, Litvack F. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart Journal 2007, 59: 165-72. PMID: 19122251.Peer-Reviewed Original ResearchConceptsStent late lossGroup 2Group 1Late lossI trialCoronary lesionsGroup 3De novo coronary lesionsSegment late lossBinary restenosis rateNative coronary lesionsNovo coronary lesionsMulti-center registryCoronary stent systemRelease formulationExtended-release formulationSmall-caliber vesselsCobalt-chromium stentNovo lesionsPrimary endpointRestenosis TrialRestenosis rateClinical outcomesFeasibility trialClinical results